Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments
- PMID: 2447178
Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments
Abstract
We report that experimental autoimmune encephalomyelitis, a T cell-mediated autoimmune disease studied as a model for multiple sclerosis, can be suppressed in Lewis rats by the oral administration of myelin basic protein (MBP). Both the clinical and histopathologic manifestations of the disease were suppressed in a dose-dependent manner. In addition, proliferative responses to MBP and, to a lesser extent, serum levels of anti-MBP antibody were suppressed by feeding MBP. Suppression of clinical and histologic disease was observed whether animals were fed MBP before or after disease induction, although suppression was more complete when rats were fed before immunization. Disease was also suppressed by the oral administration of either encephalitogenic or nonencephalitogenic fragments and decapeptides of the MBP molecule, with more complete suppression observed when nonencephalitogenic fragments were fed, suggesting that suppressor determinants exist in the MBP molecule distinct from the encephalitogenic region. The oral administration of a non-disease-inducing portion of an autoantigen represents an antigen-specific method by which an experimental autoimmune disease can be immunoregulated.
Similar articles
-
Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression.J Immunol. 1993 Dec 15;151(12):7307-15. J Immunol. 1993. PMID: 7505026
-
Exquisite peptide specificity of oral tolerance in experimental autoimmune encephalomyelitis.J Immunol. 1995 Aug 1;155(3):1599-605. J Immunol. 1995. PMID: 7543526
-
Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. II. Suppression of disease and in vitro immune responses is mediated by antigen-specific CD8+ T lymphocytes.J Immunol. 1989 Feb 1;142(3):748-52. J Immunol. 1989. PMID: 2464023
-
Oral tolerance in experimental autoimmune encephalomyelitis.Ann N Y Acad Sci. 1996 Feb 13;778:217-27. doi: 10.1111/j.1749-6632.1996.tb21130.x. Ann N Y Acad Sci. 1996. PMID: 8610975 Review.
-
[Gut mucosal immunity and oral tolerance].Nihon Rinsho. 1994 Nov;52(11):2873-9. Nihon Rinsho. 1994. PMID: 7996683 Review. Japanese.
Cited by
-
Oral tolerance to prevent anti-drug antibody formation in protein replacement therapies.Cell Immunol. 2022 Dec;382:104641. doi: 10.1016/j.cellimm.2022.104641. Epub 2022 Nov 14. Cell Immunol. 2022. PMID: 36402002 Free PMC article. Review.
-
MS as autoimmune disease: myelin antigens.Res Immunol. 1989 Feb;140(2):181-7; discussion 245-8. doi: 10.1016/0923-2494(89)90083-7. Res Immunol. 1989. PMID: 2662282 Free PMC article. Review. No abstract available.
-
Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering.Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):421-5. doi: 10.1073/pnas.89.1.421. Proc Natl Acad Sci U S A. 1992. PMID: 1370356 Free PMC article.
-
Orally tolerant CD4 T cells respond poorly to antigenic stimulation but strongly to direct stimulation of intracellular signaling pathways.Cytotechnology. 2001 Jul;36(1-3):145-53. doi: 10.1023/A:1014009328207. Cytotechnology. 2001. PMID: 19003325 Free PMC article.
-
Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope.Clin Exp Immunol. 1996 Mar;103(3):368-75. doi: 10.1111/j.1365-2249.1996.tb08289.x. Clin Exp Immunol. 1996. PMID: 8608633 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous